{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:37:51Z","timestamp":1790437071294,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12032-022-01714-y","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T10:10:46Z","timestamp":1655547046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia"],"prefix":"10.1007","volume":"39","author":[{"given":"Buket","family":"Ozel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezgi","family":"Kipcak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-4520","authenticated-orcid":false,"given":"Cigir","family":"Biray Avci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Sabour Takanlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Sabour Takanlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcin","family":"Tezcanli Kaymaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilknur","family":"Karatekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cumhur","family":"Gunduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Selvi Gunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"issue":"9","key":"1714_CR1","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.cellsig.2013.05.019","volume":"25","author":"M Mancini","year":"2013","unstructured":"Mancini M, Leo E, Takemaru K, Campi V, Borsi E, Castagnetti F, et al. Chibby drives \u03b2 catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells. Cell Signal. 2013;25(9):1820\u20137. https:\/\/doi.org\/10.1016\/j.cellsig.2013.05.019.","journal-title":"Cell Signal"},{"issue":"9","key":"1714_CR2","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/j.1349-7006.2012.02346.x","volume":"103","author":"Y Maru","year":"2012","unstructured":"Maru Y. Molecular biology of chronic myeloid leukemia. Cancer Sci. 2012;103(9):1601\u201310. https:\/\/doi.org\/10.1111\/j.1349-7006.2012.02346.x.","journal-title":"Cancer Sci"},{"key":"1714_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2147\/dddt.S80207","volume":"9","author":"R Chen","year":"2015","unstructured":"Chen R, Chen B. The role of dasatinib in the management of chronic myeloid leukemia. Drug Des Devel Ther. 2015;9:773\u20139. https:\/\/doi.org\/10.2147\/dddt.S80207.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"1714_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442\u201359. https:\/\/doi.org\/10.1002\/ajh.25011.","journal-title":"Am J Hematol"},{"issue":"2","key":"1714_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/tcrm.s3425","volume":"5","author":"DG Aguilera","year":"2009","unstructured":"Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag. 2009;5(2):281\u20139. https:\/\/doi.org\/10.2147\/tcrm.s3425.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"1714_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098859","volume":"9","author":"SK Heo","year":"2014","unstructured":"Heo SK, Noh EK, Yoon DJ, Jo JC, Park JH, Kim H. Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity. PLoS ONE. 2014;9(2): e98859. https:\/\/doi.org\/10.1371\/journal.pone.0098859.","journal-title":"PLoS ONE"},{"issue":"6","key":"1714_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.clml.2013.05.012","volume":"13","author":"E Jabbour","year":"2013","unstructured":"Jabbour E, Lipton JH. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Clin Lymphoma Myeloma Leuk. 2013;13(6):646\u201356. https:\/\/doi.org\/10.1016\/j.clml.2013.05.012.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1714_CR8","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.2147\/dddt.S85050","volume":"10","author":"D Keskin","year":"2016","unstructured":"Keskin D, Sadri S, Eskazan AE. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. Drug Des Devel Ther. 2016;10:3355\u201361. https:\/\/doi.org\/10.2147\/dddt.S85050.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"1714_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40272-018-0319-8","volume":"20","author":"EH McCafferty","year":"2018","unstructured":"McCafferty EH, Dhillon S, Deeks ED. Dasatinib: a review in pediatric chronic myeloid leukemia. Paediatr Drugs. 2018;20(6):593\u2013600. https:\/\/doi.org\/10.1007\/s40272-018-0319-8.","journal-title":"Paediatr Drugs"},{"issue":"2","key":"1714_CR10","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101(2):690\u20138. https:\/\/doi.org\/10.1182\/blood.V101.2.690.","journal-title":"Blood"},{"issue":"7","key":"1714_CR11","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","volume":"111","author":"J Wu","year":"2008","unstructured":"Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood. 2008;111(7):3821\u20139. https:\/\/doi.org\/10.1182\/blood-2007-08-109330.","journal-title":"Blood"},{"issue":"12","key":"1714_CR12","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"W Warsch","year":"2011","unstructured":"Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, H\u00f6lbl A, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117(12):3409\u201320. https:\/\/doi.org\/10.1182\/blood-2009-10-248211.","journal-title":"Blood"},{"issue":"21","key":"1714_CR13","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.4161\/cc.22387","volume":"11","author":"M Kusio-Kobialka","year":"2012","unstructured":"Kusio-Kobialka M, Podszywalow-Bartnicka P, Peidis P, Glodkowska-Mrowka E, Wolanin K, Leszak G, et al. The PERK-eIF2\u03b1 phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells. Cell Cycle. 2012;11(21):4069\u201378. https:\/\/doi.org\/10.4161\/cc.22387.","journal-title":"Cell Cycle"},{"issue":"6","key":"1714_CR14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.Cd-14-1490","volume":"5","author":"E Chevet","year":"2015","unstructured":"Chevet E, Hetz C, Samali A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov. 2015;5(6):586\u201397. https:\/\/doi.org\/10.1158\/2159-8290.Cd-14-1490.","journal-title":"Cancer Discov"},{"issue":"23","key":"1714_CR15","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.4161\/cc.22808","volume":"11","author":"D Perrotti","year":"2012","unstructured":"Perrotti D, Neviani P. Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia. Cell Cycle. 2012;11(23):4300\u20131. https:\/\/doi.org\/10.4161\/cc.22808.","journal-title":"Cell Cycle"},{"issue":"10","key":"1714_CR16","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1128\/mcb.01484-13","volume":"34","author":"A Higa","year":"2014","unstructured":"Higa A, Taouji S, Lhomond S, Jensen D, Fernandez-Zapico ME, Simpson JC, et al. Endoplasmic reticulum stress-activated transcription factor ATF6\u03b1 requires the disulfide isomerase PDIA5 to modulate chemoresistance. Mol Cell Biol. 2014;34(10):1839\u201349. https:\/\/doi.org\/10.1128\/mcb.01484-13.","journal-title":"Mol Cell Biol"},{"key":"1714_CR17","doi-asserted-by":"publisher","unstructured":"Kalathur RK, Giner-Lamia J, Machado S, Barata T, Ayasolla KR, Futschik ME. The unfolded protein response and its potential role in Huntington's disease elucidated by a systems biology approach. F1000Res 2015;4:103.https:\/\/doi.org\/10.12688\/f1000research.6358.2","DOI":"10.12688\/f1000research.6358.2"},{"issue":"1","key":"1714_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.tcb.2003.11.001","volume":"14","author":"DT Rutkowski","year":"2004","unstructured":"Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol. 2004;14(1):20\u20138. https:\/\/doi.org\/10.1016\/j.tcb.2003.11.001.","journal-title":"Trends Cell Biol"},{"key":"1714_CR19","doi-asserted-by":"publisher","first-page":"44674","DOI":"10.1038\/srep44674","volume":"7","author":"L Guo","year":"2017","unstructured":"Guo L, Chi Y, Xue J, Ma L, Shao Z, Wu J. Phosphorylated eIF2\u03b1 predicts disease-free survival in triple-negative breast cancer patients. Sci Rep. 2017;7:44674. https:\/\/doi.org\/10.1038\/srep44674.","journal-title":"Sci Rep"},{"key":"1714_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.critrevonc.2018.05.003","volume":"127","author":"M Wang","year":"2018","unstructured":"Wang M, Law ME, Castellano RK, Law BK. The unfolded protein response as a target for anticancer therapeutics. Crit Rev Oncol Hematol. 2018;127:66\u201379. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.05.003.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18","key":"1714_CR21","doi-asserted-by":"publisher","first-page":"9260","DOI":"10.1158\/0008-5472.Can-06-1586","volume":"66","author":"SP Ermakova","year":"2006","unstructured":"Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, Ma WY, et al. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res. 2006;66(18):9260\u20139. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-1586.","journal-title":"Cancer Res"},{"issue":"5","key":"1714_CR22","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1182\/blood-2011-11-394346","volume":"120","author":"CL Kriss","year":"2012","unstructured":"Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, et al. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood. 2012;120(5):1027\u201338. https:\/\/doi.org\/10.1182\/blood-2011-11-394346.","journal-title":"Blood"},{"issue":"4","key":"1714_CR23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/blood-2010-08-303099","volume":"117","author":"I Papandreou","year":"2011","unstructured":"Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S, Tam A, et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 2011;117(4):1311\u20134. https:\/\/doi.org\/10.1182\/blood-2010-08-303099.","journal-title":"Blood"},{"issue":"5","key":"1714_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ajh.21380","volume":"84","author":"C Pavlovsky","year":"2009","unstructured":"Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol. 2009;84(5):287\u201393. https:\/\/doi.org\/10.1002\/ajh.21380.","journal-title":"Am J Hematol"},{"issue":"2","key":"1714_CR25","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1007\/s13277-015-4015-9","volume":"37","author":"MK Yandim","year":"2016","unstructured":"Yandim MK, Ceylan C, Elmas E, Baran Y. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib. Tumour Biol. 2016;37(2):2365\u201378. https:\/\/doi.org\/10.1007\/s13277-015-4015-9.","journal-title":"Tumour Biol"},{"issue":"2","key":"1714_CR26","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.3747\/co.v18i2.391","volume":"18","author":"S Assouline","year":"2011","unstructured":"Assouline S, Lipton JH. Monitoring response and resistance to treatment in chronic myeloid leukemia. Curr Oncol. 2011;18(2):e71-83. https:\/\/doi.org\/10.3747\/co.v18i2.391.","journal-title":"Curr Oncol"},{"issue":"9","key":"1714_CR27","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ajh.24423","volume":"91","author":"NP Shah","year":"2016","unstructured":"Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91(9):869\u201374. https:\/\/doi.org\/10.1002\/ajh.24423.","journal-title":"Am J Hematol"},{"issue":"10","key":"1714_CR28","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","volume":"34","author":"X An","year":"2010","unstructured":"An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34(10):1255\u201368. https:\/\/doi.org\/10.1016\/j.leukres.2010.04.016.","journal-title":"Leuk Res"},{"issue":"2","key":"1714_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5732\/cjc.011.10327","volume":"31","author":"XX Peng","year":"2012","unstructured":"Peng XX, Tiwari AK, Wu HC, Chen ZS. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chin J Cancer. 2012;31(2):110\u20138. https:\/\/doi.org\/10.5732\/cjc.011.10327.","journal-title":"Chin J Cancer"},{"issue":"12","key":"1714_CR30","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1016\/j.bbamcr.2013.06.028","volume":"1833","author":"R Sano","year":"2013","unstructured":"Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta. 2013;1833(12):3460\u201370. https:\/\/doi.org\/10.1016\/j.bbamcr.2013.06.028.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1714_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7150\/ijms.29134","volume":"16","author":"R Gundamaraju","year":"2019","unstructured":"Gundamaraju R, Vemuri R, Chong WC, Bulmer AC, Eri R. Bilirubin attenuates ER stress-mediated inflammation, escalates apoptosis and reduces proliferation in the LS174T colonic epithelial cell line. Int J Med Sci. 2019;16(1):135\u201344. https:\/\/doi.org\/10.7150\/ijms.29134.","journal-title":"Int J Med Sci"},{"issue":"1","key":"1714_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.7508\/ibj.2016.01.009","volume":"20","author":"A Bazi","year":"2016","unstructured":"Bazi A, Keramati MR, Gholamin M. Role of oxidative stress in modulating unfolded protein response activity in chronic myeloid leukemia cell line. Iran Biomed J. 2016;20(1):63\u20137. https:\/\/doi.org\/10.7508\/ibj.2016.01.009.","journal-title":"Iran Biomed J"},{"issue":"1","key":"1714_CR33","doi-asserted-by":"publisher","DOI":"10.4161\/23723556.2014.975089","volume":"2","author":"AD Garg","year":"2015","unstructured":"Garg AD, Maes H, van Vliet AR, Agostinis P. Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress. Mol Cell Oncol. 2015;2(1): e975089. https:\/\/doi.org\/10.4161\/23723556.2014.975089.","journal-title":"Mol Cell Oncol"},{"issue":"23","key":"1714_CR34","doi-asserted-by":"publisher","first-page":"20915","DOI":"10.1074\/jbc.M212328200","volume":"278","author":"RK Reddy","year":"2003","unstructured":"Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 2003;278(23):20915\u201324. https:\/\/doi.org\/10.1074\/jbc.M212328200.","journal-title":"J Biol Chem"},{"key":"1714_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12890-015-0127-7","volume":"15","author":"A Aquino-G\u00e1lvez","year":"2015","unstructured":"Aquino-G\u00e1lvez A, Gonz\u00e1lez-\u00c1vila G, P\u00e9rez-Rodr\u00edguez M, Partida-Rodr\u00edguez O, Nieves-Ram\u00edrez M, Pi\u00f1a-Ram\u00edrez I, et al. Analysis of heat shock protein 70 gene polymorphisms Mexican patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2015;15:129. https:\/\/doi.org\/10.1186\/s12890-015-0127-7.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"1714_CR36","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1038\/s41598-017-03814-6","volume":"7","author":"SH Park","year":"2017","unstructured":"Park SH, Kim WJ, Li H, Seo W, Park SH, Kim H, et al. Anti-leukemia activity of a Hsp70 inhibitor and its hybrid molecules. Sci Rep. 2017;7(1):3537. https:\/\/doi.org\/10.1038\/s41598-017-03814-6.","journal-title":"Sci Rep"},{"issue":"1","key":"1714_CR37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/cdd.2014.116","volume":"22","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Kim JM, Kim KH, Heo JI, Kwak SJ, Han JA. Genotoxic stress\/p53-induced DNAJB9 inhibits the pro-apoptotic function of p53. Cell Death Differ. 2015;22(1):86\u201395. https:\/\/doi.org\/10.1038\/cdd.2014.116.","journal-title":"Cell Death Differ"},{"issue":"7","key":"1714_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrm2199","volume":"8","author":"D Ron","year":"2007","unstructured":"Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8(7):519\u201329. https:\/\/doi.org\/10.1038\/nrm2199.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"1714_CR39","doi-asserted-by":"publisher","first-page":"736","DOI":"10.4161\/cbt.5.7.2969","volume":"5","author":"MJ Mann","year":"2006","unstructured":"Mann MJ, Hendershot LM. UPR activation alters chemosensitivity of tumor cells. Cancer Biol Ther. 2006;5(7):736\u201340. https:\/\/doi.org\/10.4161\/cbt.5.7.2969.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"1714_CR40","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/sj.cdd.4401984","volume":"14","author":"Y Kouroku","year":"2007","unstructured":"Kouroku Y, Fujita E, Tanida I, Ueno T, Isoai A, Kumagai H, et al. ER stress (PERK\/eIF2alpha phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. Cell Death Differ. 2007;14(2):230\u20139. https:\/\/doi.org\/10.1038\/sj.cdd.4401984.","journal-title":"Cell Death Differ"},{"issue":"4","key":"1714_CR41","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bbrc.2018.09.032","volume":"504","author":"Y Kato","year":"2018","unstructured":"Kato Y, Kunimasa K, Sugimoto Y, Tomida A. BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562 cells. Biochem Biophys Res Commun. 2018;504(4):721\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2018.09.032.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1714_CR42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1369\/jhc.5A6785.2005","volume":"54","author":"WG Jiang","year":"2006","unstructured":"Jiang WG, Raz A, Douglas-Jones A, Mansel RE. Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer. J Histochem Cytochem. 2006;54(2):231\u201341. https:\/\/doi.org\/10.1369\/jhc.5A6785.2005.","journal-title":"J Histochem Cytochem"},{"issue":"40","key":"1714_CR43","doi-asserted-by":"publisher","first-page":"29305","DOI":"10.1074\/jbc.M704069200","volume":"282","author":"LD Kojic","year":"2007","unstructured":"Kojic LD, Joshi B, Lajoie P, Le PU, Cox ME, Turbin DA, et al. Raft-dependent endocytosis of autocrine motility factor is phosphatidylinositol 3-kinase-dependent in breast carcinoma cells. J Biol Chem. 2007;282(40):29305\u201313. https:\/\/doi.org\/10.1074\/jbc.M704069200.","journal-title":"J Biol Chem"},{"key":"1714_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100344","author":"EP McGrath","year":"2018","unstructured":"McGrath EP, Logue SE, Mnich K, Deegan S, J\u00e4ger R, Gorman AM, Samali A. The unfolded protein response in breast cancer. Cancers (Basel). 2018. https:\/\/doi.org\/10.3390\/cancers10100344.","journal-title":"Cancers (Basel)"},{"issue":"50","key":"1714_CR45","doi-asserted-by":"publisher","first-page":"83278","DOI":"10.18632\/oncotarget.13086","volume":"7","author":"J Strietz","year":"2016","unstructured":"Strietz J, Stepputtis SS, Preca BT, Vannier C, Kim MM, Castro DJ, et al. ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer. Oncotarget. 2016;7(50):83278\u201393. https:\/\/doi.org\/10.18632\/oncotarget.13086.","journal-title":"Oncotarget"},{"issue":"17","key":"1714_CR46","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.1158\/0008-5472.Can-07-0045","volume":"67","author":"KD Bromberg","year":"2007","unstructured":"Bromberg KD, Kluger HM, Delaunay A, Abbas S, DiVito KA, Krajewski S, Ronai Z. Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer. Cancer Res. 2007;67(17):8172\u20139. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-0045.","journal-title":"Cancer Res"},{"issue":"3","key":"1714_CR47","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1053\/j.gastro.2018.10.031","volume":"156","author":"F Hua","year":"2019","unstructured":"Hua F, Shang S, Yang YW, Zhang HZ, Xu TL, Yu JJ, et al. TRIB3 interacts with \u03b2-catenin and TCF4 to increase stem cell features of colorectal cancer stem cells and tumorigenesis. Gastroenterology. 2019;156(3):708-721.e715. https:\/\/doi.org\/10.1053\/j.gastro.2018.10.031.","journal-title":"Gastroenterology"},{"issue":"1","key":"1714_CR48","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1038\/s41467-019-13700-6","volume":"10","author":"JM Yu","year":"2019","unstructured":"Yu JM, Sun W, Wang ZH, Liang X, Hua F, Li K, et al. TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription. Nat Commun. 2019;10(1):5720. https:\/\/doi.org\/10.1038\/s41467-019-13700-6.","journal-title":"Nat Commun"},{"key":"1714_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/324815","volume":"2015","author":"SE van der Krieken","year":"2015","unstructured":"van der Krieken SE, Popeijus HE, Mensink RP, Plat J. CCAAT\/enhancer binding protein \u03b2 in relation to ER stress, inflammation, and metabolic disturbances. Biomed Res Int. 2015;2015: 324815. https:\/\/doi.org\/10.1155\/2015\/324815.","journal-title":"Biomed Res Int"},{"issue":"3","key":"1714_CR50","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1182\/bloodadvances.2018020503","volume":"3","author":"A Yokota","year":"2019","unstructured":"Yokota A, Hirai H, Sato R, Adachi H, Sato F, Hayashi Y, et al. C\/EBP\u03b2 is a critical mediator of IFN-\u03b1-induced exhaustion of chronic myeloid leukemia stem cells. Blood Adv. 2019;3(3):476\u201388. https:\/\/doi.org\/10.1182\/bloodadvances.2018020503.","journal-title":"Blood Adv"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01714-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01714-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01714-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T05:21:23Z","timestamp":1658294483000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01714-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1714"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01714-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,18]]},"assertion":[{"value":"1 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"126"}}